Clinical Trials
The INVENT global phase 2 clinical study
A study designed to evaluate the efficacy and safety of inhaled IFN-β (SNG001) in treating severely ill patients infected with a respiratory virus admitted to the ICU and receiving mechanical ventilation
SG021 Trial
Phase 2 double-blind, placebo-controlled trial of IFN-β, SNG001, in mechanically-ventilated patients infected with a range of respiratory viruses.
A summary of the Trial Protocol is available on the ISRCTN registry – The UK’s Clinical Study Registry, available here.
A summary of the Study Results.